Liew-Spilger, Alyson E.Sorg, Nikki R.Brenner, Toby J.Langford, Jack H.Berquist, MargaretMark, Natalie M.Moore, Spencer H.Mark, JulieBaumgartner, SaraAbernathy, Mary P.2023-03-082023-03-082021-08-31Liew-Spilger AE, Sorg NR, Brenner TJ, et al. Viscoelastic Hemostatic Assays for Postpartum Hemorrhage. J Clin Med. 2021;10(17):3946. Published 2021 Aug 31. doi:10.3390/jcm10173946https://hdl.handle.net/1805/31708This article discusses the importance and effectiveness of viscoelastic hemostatic assays (VHAs) in assessing hemostatic competence and guiding blood component therapy (BCT) in patients with postpartum hemorrhage (PPH). In recent years, VHAs such as thromboelastography and rotational thromboelastometry have increasingly been used to guide BCT, hemostatic adjunctive therapy and prohemostatic agents in PPH. The three pillars of identifying hemostatic competence include clinical observation, common coagulation tests, and VHAs. VHAs are advantageous because they assess the cumulative contribution of all components of the blood throughout the entire formation of a clot, have fast turnaround times, and are point-of-care tests that can be followed serially. Despite these advantages, VHAs are underused due to poor understanding of correct technique and result interpretation, a paucity of widespread standardization, and a lack of large clinical trials. These VHAs can also be used in cases of uterine atony, preeclampsia, acute fatty liver of pregnancy, amniotic fluid embolism, placental abruption, genital tract trauma, surgical trauma, and inherited and prepartum acquired coagulopathies. There exists an immediate need for a point-of-care test that can equip obstetricians with rapid results on developing coagulopathic states. The use of VHAs in predicting and treating PPH, although in an incipient state, can fulfill this need.en-USAttribution 4.0 InternationalThromboelastographyRotational thromboelastometryPostpartum hemorrhagePregnancyBlood component transfusionBlood coagulationObstetricsDisseminated intravascular coagulationAmniotic fluid embolismvon Willebrand factorArticle